Differentiated thyroid carcinomas and their B7H1 shield

Future Oncology

Volumn 9, Issue 10, 2013, Pages 1417-1419

  Cunha, Lucas Leite ^a   Marcello, Marjory Alana ^a   Vassallo, José ^a,b   Ward, Laura Sterian ^a  

^a UNIVERSITY OF CAMPINAS   (Brazil)

^b A C CAMARGO CANCER CENTER   (Brazil)

Author keywords

B7H1; differentiated thyroid carcinoma; tumor immunology

Indexed keywords

IPILIMUMAB; PROGRAMMED DEATH 1 LIGAND 1; SIPULEUCEL T;

CHRONIC INFLAMMATION; DIFFERENTIATED THYROID CANCER; EDITORIAL; HUMAN; IMMUNE RESPONSE; IMMUNOLOGICAL TOLERANCE; IMMUNOTHERAPY; MELANOMA; NEOPLASM; PHENOTYPE; PRIORITY JOURNAL; PROSTATE CANCER; TUMOR GROWTH; UPREGULATION;

ANTIGENS, CD274; HUMANS; NEOPLASM GRADING; THYROID NEOPLASMS;

EID: 84885625010     PISSN: 14796694     EISSN: 17448301     Source Type: Journal    
DOI: 10.2217/fon.13.89     Document Type: Editorial

References (20)

1. Muzza M, Degl'innocenti D, Colombo C et al. The tight relationship between papillary thyroid cancer, autoimmunity and inflammation: clinical and molecular studies. Clin. Endocrinol. 72(5), 702-708 (2010
2. De Vries AC, Van Grieken NC, Looman CW et al. Gastric cancer risk in patients with premalignant gastric lesions: a nationwide cohort study in The Netherlands. Gastroenterology 134(4), 945-952 (2008 (Pubitemid 351451990)
3. Cunha LL, Tincani AJ, Assumpcao LV, Soares FA, Vassallo J, Ward LS. Interleukin-10 but not interleukin-18 may be associated with the immune response against well-differentiated thyroid cancer. Clinics 66(7), 1203-1208 (2011
4. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013. CA Cancer J. Clin. 63(1), 11-30 (2013
5. Kantoff PW, Higano CS, Shore ND et al. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N. Engl. J. Med. 363(5), 411-422 (2010
6. Hodi FS, O'Day SJ, McDermott DF et al. Improved survival with ipilimumab in patients with metastatic melanoma. N. Engl. J. Med. 363(8), 711-723 (2010
7. Brahmer JR, Tykodi SS, Chow LQ et al. Safety and activity of anti-PD-L1antibody in patients with advanced cancer. N. Engl. J. Med. 366(26), 2455-2465 (2012
8. Cunha LL, Ward LS. Concurrent lymphocytic thyroiditis is associated to less aggressive papillary thyroid carcinomas. Eur. Arch. Otorhinolaryngol. 269(2), 699-700 (2012
9. Gogali F, Paterakis G, Rassidakis GZ et al. Phenotypical analysis of lymphocytes with suppressive and regulatory properties (Tregs) and NK cells in the papillary carcinoma of thyroid. J. Clin. Endocrinol. Metab. 97(5), 1474-1482 (2012
10. French JD, Weber ZJ, Fretwell DL, Said S, Klopper JP, Haugen BR. Tumor-associated lymphocytes and increased FoxP3+ regulatory T cell frequency correlate with more aggressive papillary thyroid cancer. J. Clin. Endocrinol. Metab. 95(5), 2325-2333 (2010
11. Zhou G, Drake CG, Levitsky HI. Amplification of tumor-specific regulatory T cells following therapeutic cancer vaccines. Blood 107(2), 628-636 (2006 (Pubitemid 43076387)
12. Hamanishi J, Mandai M, Iwasaki M et al. Programmed cell death 1 ligand 1 and tumor-infiltrating CD8+ T lymphocytes are prognostic factors of human ovarian cancer. Proc. Natl Acad. Sci. USA 104(9), 3360-3365 (2007 (Pubitemid 46364164)
13. Dong H, Strome SE, Salomao DR et al. Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion. Nat. Med. 8(8), 793-800 (2002
14. Thompson RH, Kuntz SM, Leibovich BC et al. Tumor B7-H1 is associated with poor prognosis in renal cell carcinoma patients with long-term follow-up. Cancer Res. 66(7), 3381-3385 (2006
15. Cunha LL, Marcello MA, Morari EC et al. Differentiated thyroid carcinomas may elude the immune system by B7H1 upregulation. Endocr. Relat. Cancer 20(1), 103-110 (2013
16. Routh JC, Ashley RA, Sebo TJ et al. B7-H1 expression in Wilms tumor: correlation with tumor biology and disease recurrence. J. Urol. 179(5), 1954-1960 (2008
17. Yao Y, Tao R, Wang X, Wang Y, Mao Y, Zhou LF. B7-H1 is correlated with malignancy-grade gliomas but is not expressed exclusively on tumor stem-like cells. Neuro. Oncol. 11(6), 757-766 (2009
18. French JD, Kotnis GR, Said S et al. Programmed death-1+ T cells and regulatory T cells are enriched in tumor-involved lymph nodes and associated with aggressive features in papillary thyroid cancer. J. Clin. Endocrinol. Metab. 97(6), e934-e943 (2012
19. Fife BT, Pauken KE, Eagar TN et al. Interactions between PD-1 and PD-L1 promote tolerance by blocking the TCR-induced stop signal. Nat. Immunol. 10(11), 1185-1192 (2009
20. Iwai Y, Ishida M, Tanaka Y, Okazaki T, Honjo T, Minato N. Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade. Proc. Natl Acad. Sci. USA 99(19), 12293-12297 (2002).